Clinical trial
Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's…
NCT00062244 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00062244 |
|---|---|
| Title | Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia |
| Official title | Phase I/II Study of G3139 (Genasense) in Patients With Waldenstrom's Macroglobulinemia |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Waldenström Macroglobulinemia |
| Intervention type | Biological |
| Interventions | oblimersen sodium |
| Enrollment | 58 |
| Start date | May 1, 2003 |
| Primary completion | Jun 1, 2007 |
| First posted | Jun 6, 2003 |
| Last update posted | Jun 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: